Patients with conditions such as hypertension, heart failure, chronic kidney disease, and post-myocardial infarction are primary beneficiaries of ACE inhibitors. Epidemiological studies have shown that these medications can significantly reduce the risk of cardiovascular events and mortality in these populations.
